Navigation Links
UFE Highly Effective in Cases Where Focused Ultrasound to Treat Uterine Fibroids Failed
Date:3/18/2008

Significant Relief of Symptoms Noted From Uterine Fibroid Embolization

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- Uterine fibroid embolization (UFE), a minimally invasive interventional radiology treatment for uterine fibroids, provides significant relief of symptoms for women whose focused ultrasound (FUS) treatment failed, according to a study released today during the Society of Interventional Radiology's 33rd Annual Scientific Meeting in Washington, D.C. Primary care physicians and gynecologists can feel confident in informing patients that a failed FUS treatment does not require subsequent gynecological surgery. Those women can be successfully treated with UFE. Patients with a single large fibroid are candidates for FUS; patients with many fibroids, which is more often the case, would be better treated with UFE. There is limited long-term follow-up data for FUS and limited information on fibroid recurrence rates. In this retrospective study from Boston's Brigham and Women's Hospital, seven post-FUS patients who experienced therapeutic failure and were subsequently re-treated with UFE were reviewed. In all patients, their symptoms -- such as heavy menstrual bleeding and the sensation of fullness or pressure in the lower abdomen -- improved.

"FUS is a newer procedure for uterine fibroids and whether it provides sustained symptom relief is still being evaluated. My research shows that when FUS fails, these women could benefit from uterine fibroid embolization," said Alisa Suzuki, M.D., interventional radiologist at Brigham and Women's Hospital.

Uterine fibroids are noncancerous (benign) growths that develop in the muscular wall of the uterus and are treated only if they are causing bothersome symptoms. With UFE, an interventional radiologist inserts a catheter into the femoral artery and using real-time imaging, guides the catheter up the artery and then releases tiny particles, the size of grains of sand, into the uterine ar
'/>"/>

SOURCE Society of Interventional Radiology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
2. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
3. 18F-DG PET/CT can highly increase the detection of colorectal cancer
4. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
5. CT angiography highly accurate, multicenter trials show
6. CT Angiography Highly Accurate: Multicenter Trials Show
7. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
8. Highly Promising Dutch Research Into Alzheimers Disease and Parkinsons Disease
9. Songbirds offer clues to highly practiced motor skills in humans
10. LASIK works well, according to long-term study of highly myopic patients
11. Researchers find less invasive, highly accurate methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...ug. 29 /PRNewswire-FirstCall/ -- Landauer, Inc. (N...ors declared a regular,quarterly cash dividend of ...008. The dividend will be paid on October 3, 2008,... About Landauer, Landauer is the leading provide... and environmental radiation exposure. For more th...
(Date:8/29/2008)...fic obligation reduced from $250 to $19 million, ...oston Scientific,Corporation (NYSE: BSX ) today a... Texas found two patents of Medtronic, Inc. (NYSE:...ng the prosecution of the patents,before the Unite... previously found that certain Boston Scientific b...
(Date:8/29/2008)... Dr. Milton Owens and the Coastal Center for O...ia to provide protection for cash paying patients ...ic community is benefiting. , .... Milton Owens and the Coastal Center for Obesity ...rovide protection for cash paying patients in the ...
(Date:8/29/2008)... Trusted life science software provider allows...ngage via GSA. , Reston, ...erging software engineering firm dedicated to the...ral Services Administration (GSA) Contract. The GS...h the ability to conveniently engage 5AM Solutions...
Breaking Medicine News(10 mins):Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2Health News:Federal and State Agencies Have Easier Access to 5AM Solutions' Award-Winning Software Services 2
... Citys smoking rate has shown a decline, thanks to...okers to kick the habit. The statistics in the 200...0%, in comparison to 2002 figures. Over the past y...rom 22.5% to 19.9%) and among Hispanics (from 20.2...
... molecular on switch triggers gene activity that ...abilities to glucose production in the liver was ...earch hospital . The on switch, a protein called...ule that binds to a section of DNA near a gene and...
... in Tamil Nadu, who allegedly tried to get his 15-... to perform a caesarean operation , today said the... him. Dr. Murugan rubbished the media reports that...n Dhileepan Raj, a tenth standard student, operati...
...stoma typically occurs as a solid tumor in the ab...veloping in the network of the body's sympathetic ... rare, but among them, neuroblastoma is a special ...t of all childhood cancers, but 15 percent of chil...
Other Medicine News:Health News:New York Records Decline in Smoking Rate 2Health News:Research Studies on Molecular Switches of Gene 2Health News:The Bottleneck in Neuroblastoma 2
(Date:8/27/2008)...in Parts of Bucks, Delaware, Montgomery,Philadelp...e-USNewswire/ -- After encouraging,results followi...tment of,Environmental Protection will continue it...st the mosquito-borne West Nile virus., Targeted ....m. and,midnight in portions of Bucks, Delaware, M...
(Date:8/27/2008)..., melphalan and prednisone arm demonstrated a, si... complete response -, CAMBRIDGE, Mass., Aug. 27 /...pany today announced the publication of results fr... trial in this week,s edition of the,New England J...nt survival,benefit and a 30 percent complete remi...
(Date:8/27/2008)...7 /-, - Oralair(R) Grasses...acodynamic Study Conducted in an Allergen Challeng... positive results of a new study,conducted in an A...alair(R) Grasses included 86 adult patients expose...nt durations: 1 week, 1 month,2 and 4 months with...
(Date:8/27/2008)...rom BLISS-52 trial, expected by mid-2009 - - Data...fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewswire-... HGSI ) today announced it has completed enrollme...wo pivotal Phase 3,randomized clinical trials of L... systemic lupus erythematosus (SLE). Belimumab is ...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Hiemstra Approved to Manufacture Medical Devices in New CER 9345 1Hiemstra Approved to Manufacture Medical Devices in New CER 9345 2TeamStaff Receives Nasdaq Determination Letter 9340 1TeamStaff Receives Nasdaq Determination Letter 9340 2TeamStaff Receives Nasdaq Determination Letter 9340 3Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 1Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 2Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 3Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Cli 1178 4Chromosome Abnormalities Raise Risk for Autism 9333 1Chromosome Abnormalities Raise Risk for Autism 9333 2Chromosome Abnormalities Raise Risk for Autism 9333 3Chromosome Abnormalities Raise Risk for Autism 9333 4
...Family History of ESRD Are at High,Risk , ,WASHIN...f U.S.,adults have a family history of end-stage r...to be at increased risk of developing,kidney disea...l of,the American Society of Nephrology. , "A fami...frican-Americans, who are also at substantially hi...
...ibody significantly reduced the number of,new or e...bmitted,for presentation at upcoming medical meeti...12, 2007,/PRNewswire-FirstCall/ -- Biogen Idec, In...hat the ongoing CHOICE trial, a Phase 2,randomize...zumab,met its primary endpoint in relapsing multi...
Other Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 2Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 3Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 4Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis 5
...gnostics is a leading provider of immunofluorescen... that includes kits for autoimmune diseases, infec...onjugates and components. Our Impact IFA Test Syst...it sizes to choose from. Kit components include su...
...gnostics is a leading provider of immunofluorescen... that includes kits for autoimmune diseases, infec...onjugates and components. Our Impact IFA Test Syst...it sizes to choose from. Kit components include su...
...gnostics is a leading provider of immunofluorescen... that includes kits for autoimmune diseases, infec...onjugates and components. Our Impact IFA Test Syst...it sizes to choose from. Kit components include su...
...ELISA products make us a leader in this field. Wit...into the busy laboratory, our Infectious Disease E...n-to-run consistency. Our Infectious Disease ELISA...e range of serological assays including ToRCH, EBV...
Medicine Products: